论文部分内容阅读
目的：了解急性白血病患者血浆可溶性Ｆａｓ（ｓＦａｓ）受体水平及其意义。方法：用酶联免疫吸附试验法（ＥＬＩＳＡ）检测３０例急性白血病患者的血浆ｓＦａｓ含量，并与正常对照组比较。结果：难治复发患者ｓＦａｓ含量（ＡＮＬＬ９．６９±３．５１μｇ／Ｌ； ｎ＝８，ＡＬＬ７．１４±２．１８μｇ／Ｌ； ｎ＝７）显著高于（ Ｐ＜０．０１）正常对照（３．４９±２．３６μｇ／Ｌ）和ＣＲ组（ＡＮＬＬ４．２３±１． ９８μｇ／Ｌ；ｎ＝８，ＡＬＬ ３．７２±０．７２μｇ／Ｌ； ｎ＝７）。 ＡＮＬＬ与 ＡＬＬ患者 ｓＦａｓ水平比较，差异无显著性（ Ｐ ＞０． ０５）。结论：初步提示血浆ｓＦａｓ水平升高与急性白血病预后不良有关。
Objective: To understand the plasma levels of soluble Fas (sFas) receptors and its significance in patients with acute leukemia. Methods: Plasma sFas levels in 30 acute leukemia patients were detected by enzyme-linked immunosorbent assay (ELISA) and compared with the normal control group. Results: The sFas level in patients with relapse and relapse (ANLL9.69±3.51μg/L; n=8, ALL7.14±2.18μg/L; n=7) was significantly higher than that of normal controls (P<0.01). 3.49±2.36 μg/L) and CR groups (ANLL 4.23±1.98 μg/L; n=8, ALL 3.72±0.72 μg/L; n=7). There was no significant difference in sFas levels between patients with ANLL and ALL (P > 0.05). Conclusion: It is suggested that the increase of plasma sFas level is related to the poor prognosis of acute leukemia.